drugset / Trial / NCT02493582
The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of Apatinib combined with cytokine-induced killer cell (CIK) vs Apatinib alone as the third line therapy for advanced lung adenocarcinoma patients with wild-type EGFR
Timeline
- Start
- 2015-07
- Primary completion
- 2030-07
- Completion
- 2033-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CIK cells | Cell therapy | — | — |
| Background | Rivoceranib | Small molecule | 850 mg | Oral |